From the Ophthalmology Department (Lay Suan, Ken, Mansurali), Penang General Hospital, Georgetown Penang, and the Universiti Kebangsaan Malaysia Medical Centre (Hamzah), Kuala Lumpur, Malaysia.
From the Ophthalmology Department (Lay Suan, Ken, Mansurali), Penang General Hospital, Georgetown Penang, and the Universiti Kebangsaan Malaysia Medical Centre (Hamzah), Kuala Lumpur, Malaysia.
J Cataract Refract Surg. 2017 Aug;43(8):1031-1035. doi: 10.1016/j.jcrs.2017.05.031.
To evaluate the efficacy and safety of intracameral mydriatics (lidocaine 1.0% and phenylephrine 1.5%) versus topical mydriatics (phenylephrine 2.5% and tropicamide 1.0%) in pupil dilation for phacoemulsification surgery in Malaysians.
Department of Ophthalmology, Penang General Hospital, Georgetown Penang, Malaysia.
Prospective comparative case series.
Patients with immature cataract were randomized to the topical mydriatic group (topical group) or intracameral mydriatic group (intracameral group). Patients with small pupils and complicated cataracts were excluded. Pupil diameter changes were measured throughout the surgery. Additional pupil dilation maneuvers and complications were recorded.
The study comprised 112 patients. There was no difference in mean pupil dilation between the intracameral group (4.86 mm ± 0.74 [SD]) and the topical group (4.88 ± 0.91 mm) (P = .86). However, the mean pupil size before capsulorhexis in the topical group (7.23 ± 1.08 mm) was significantly larger than in the intracameral group (6.40 ± 0.80 mm) (P = .01). The pupils in the intracameral group continued to dilate during surgery (0.44 ± 0.62 mm), while those in the topical group constricted (-0.41 ± 1.04 mm) (P < .001). Three patients in the intracameral group and 6 in the topical group required additional maneuvers for pupil dilation (P = .49). Each group had 1 complication (P = 1.00).
Intracameral mydriatic agents dilated heavily pigmented pupils for phacoemulsification cataract surgery. However, in the early stages of surgery, pupil dilation was slower than with topical agents.
评估在马来人中,房水内散瞳剂(利多卡因 1.0%和苯肾上腺素 1.5%)与局部散瞳剂(苯肾上腺素 2.5%和托吡卡胺 1.0%)在白内障超声乳化手术中的散瞳效果和安全性。
马来西亚槟城总医院眼科。
前瞻性比较病例系列。
将不成熟白内障患者随机分为局部散瞳组(局部组)或房水内散瞳组(房水组)。排除瞳孔小和复杂白内障的患者。测量手术过程中的瞳孔直径变化。记录额外的瞳孔扩张操作和并发症。
研究共纳入 112 例患者。房水组(4.86±0.74 [SD]mm)与局部组(4.88±0.91mm)的平均瞳孔扩张无差异(P=0.86)。然而,局部组在撕囊前的平均瞳孔大小(7.23±1.08mm)明显大于房水组(6.40±0.80mm)(P=0.01)。房水组的瞳孔在手术过程中持续扩张(0.44±0.62mm),而局部组的瞳孔收缩(-0.41±1.04mm)(P<0.001)。房水组有 3 例和局部组有 6 例需要额外的瞳孔扩张操作(P=0.49)。两组各有 1 例并发症(P=1.00)。
房水内散瞳剂可使色素沉着严重的瞳孔扩张,用于白内障超声乳化手术。然而,在手术的早期阶段,瞳孔扩张速度比局部散瞳剂慢。